ArticleJournal of community hospital internal medicine perspectives2025
Acute Kidney Injury (AKI) in Adults With Leukemia: A Nationwide Inpatient Retrospective Analysis.
Article in Journal of community hospital internal medicine perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leukemia ranks among the top three cancers in those who have Acute Kidney Injury (AKI), with an incidence of 7.5 % in hematological malignancies. Through this study, we aimed to assess the mortality of severe sepsis (SS), thrombocytopenia, and metabolic encephalopathy (MetE) in Leukemia with AKI. Methods: We conducted a retrospective analysis using the National Inpatient Sample (2018-2021). Adults with Leukemia primarily admitted with AKI were included, and mortality was calculated. Patients were stratified by SS, thrombocytopenia, and MetE. Propensity matching for age over 60 and gender, and multivariate regression were performed with p ≤ 0.05. Results: Among 388,449 Leukemia patients, 2.5 % had AKI. The mortality in AML was 7 % and CML was 5.7 %. In Leukemia, mortality risk was lower in the AKI cohort than in those without AKI (aOR 0.04, p < 0.01). In the AKI cohort, individuals aged >60 years showed increased mortality (p < 0.001). Race, gender, hematopoietic stem cell transplant, and inpatient hemodialysis did not alter mortality (p > 0.05). We identified increased mortality risk with SS (aOR 38.2, p < 0.001), thrombocytopenia (aOR 1.8, p < 0.001), and MetE (aOR 3.3, p < 0.001). Additionally, patients with these outcomes required blood transfusions, vasopressors, and invasive ventilation (p < 0.001). Conclusion: These findings underscore the lower mortality of AKI in Leukemia but highlight higher mortality rates in association with sepsis, thrombocytopenia, and metabolic encephalopathy. Managing AKI also requires appropriate antibiotic selection and a thorough evaluation for bone marrow dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.